Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $8M (down 60.1% year over year) with net income of −$131M.
Q2 2026 key financials · XBRL
- Revenue
- $8M
- −60.1% YoY · +18.5% QoQ
- Net income
- −$131M
- +23.8% YoY · −11.5% QoQ
- Operating margin
- -1759.4%
- EPS (diluted)
- −$0.25
- +39.0% YoY · −13.6% QoQ
Source: XBRL data from the RECURSION PHARMACEUTICALS, INC. (RXRX) Q2 2026 10-Q on SEC EDGAR. USD.
RECURSION PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $7.7M, down 60% YoY from $19.2M, primarily lower Roche revenue recognition
- Net loss $131.0M vs $171.9M YoY, with operating loss $135.0M vs $176.2M
- Platform R&D $42.1M, down 47% YoY; clinical R&D $23.7M, up 21%
- Cash, cash equivalents and restricted cash $556.8M vs $753.9M at December 31, 2025
- Operating cash used $187.0M vs $208.4M; no TD Cowen equity sales as of June 30, 2026
- Near-term milestones: REC-7735 Phase 1/2 initiation and FDA registrational-path update for REC-4881 expected in 2H26
Risk Factors
- No Risk Factors section provided; no new, changed, or carried-forward risks identifiable
- Lease extension through May 31, 2034, creating longer-term facility commitment
- Sublease of approximately 66,000 square feet scheduled through May 31, 2032
- Unregistered stock-option exercises: 4,800 Class A shares for approximately $2 thousand
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RECURSION PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.